Claims
- 1. A compound of Formula I
- 2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is N(R6)C(O).
- 3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is C≡C.
- 4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y3 and Y4 are taken together to form a diradical group selected from:
- 5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y3 and Y4 are taken together to form a diradical group selected from:
- 6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y3 and Y4 are taken together to form a diradical group selected from:
- 7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y3 and Y4 are taken together to form a diradical group selected from:
- 8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is OH.
- 9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is H.
- 10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R1 is independently selected from:
Phenyl-(C1-C8 alkylenyl); Substituted phenyl-(C1-C8 alkylenyl); 5- or 6-membered heteroaryl-(C1-C8 alkylenyl); Substituted 5- or 6-membered heteroaryl-(C1-C8 alkylenyl); 8- to 10-membered heterobiaryl-(C1-C8 alkylenyl); and Substituted 8- to 10-membered heterobiaryl-(C1-C8 alkylenyl); and R2 is independently selected from: Phenyl-(C1-C8 alkylenyl)m; Substituted phenyl-(C1-C8 alkylenyl)m; 5- or 6-membered heteroaryl-(C1-C8 alkylenyl)m; Substituted 5- or 6-membered heteroaryl-(C1-C8 alkylenyl)m; 8- to 10-membered heterobiaryl-(C1-C8 alkylenyl)m; and Substituted 8- to 10-membered heterobiaryl-(C1-C8 alkylenyl)m; wherein m is an integer of 0 or 1; and
- 11. A compound of Formula XIV
- 12. The compound according to claim 11, selected from:
4-(6-Benzylcarbamoyl-4-hydroxy-quinolin-3-ylmethyl)-benzoic acid; 4-[4-Hydroxy-6-(4-methoxy-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid; 4-[4-Hydroxy-6-(3-methoxy-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid; 4-{4-Hydroxy-6-[(2-methoxy-pyridin-4-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-{4-Hydroxy-6-[(pyridin-4-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-{4-Hydroxy-6-[(pyridin-3-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-[6-(4-Cyano-benzylcarbamoyl)-4-hydroxy-quinolin-3-ylmethyl]-benzoic acid; 4-[4-Hydroxy-6-(4-methyl-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid; 4-[4-Hydroxy-6-(4-trifluoromethyl-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid; 4-[6-(4-Fluoro-benzylcarbamoyl)-4-hydroxy-quinolin-3-ylmethyl]-benzoic acid; 4-[6-(4-Chloro-benzylcarbamoyl)-4-hydroxy-quinolin-3-ylmethyl]-benzoic acid; 4-[6-(4-Bromo-benzylcarbamoyl)-4-hydroxy-quinolin-3-ylmethyl]-benzoic acid; 4-[4-Hydroxy-6-(4-iodo-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid; 4-[4-Hydroxy-6-(4-methanesulfonyl-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid; 4-[4-Hydroxy-6-(4-sulfo-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid; 4-[4-Hydroxy-6-(4-sulfamoyl-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid; 4-[6-(4-Dimethylsulfamoyl-benzylcarbamoyl)-4-hydroxy-quinolin-3-ylmethyl]-benzoic acid; 4-{6-[4-(Aziridine-1-sulfonyl)-benzylcarbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid; or a pharmaceutically acceptable salt thereof.
- 13. The compound according to claim 11, selected from:
4-{4-Hydroxy-6-[(piperidin-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-{4-Hydroxy-6-[(4-methyl-piperazin-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-{4-Hydroxy-6-[(morpholin-4-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-{4-Hydroxy-6-[(pyrrolidin-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-{4-Hydroxy-6-[(pyrrol-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-{4-Hydroxy-6-[(imidazol-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-{4-Hydroxy-6-[([1,2,4]triazol-4-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-{4-Hydroxy-6-[(tetrazol-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-{6-[(2,3-Dihydro-benzo[b]furan-5-ylmethyl)-carbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid; 4-{6-[(2,3-Dihydro-benzo[b]thiophen-5-ylmethyl)-carbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid; 4-{6-[(2,3-Dihydro-1H-indol-5-ylmethyl)-carbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid; 4-{4-Hydroxy-6-[(1H-indol-5-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid; 4-(6-[(Benzo[b]thiophen-5-ylmethyl)-carbamoyl]4-hydroxy-quinolin-3-ylmethyl}-benzoic acid; 4-{6-[(Benzofuran-5-ylmethyl)-carbamoyl]4-hydroxy-quinolin-3-ylmethyl}-benzoic acid; and 4-{6-[(Benzooxazol-5-ylmethyl)-carbamoyl]4-hydroxy-quinolin-3-ylmethyl}-benzoic acid; or a pharmaceutically acceptable salt thereof.
- 14. A pharmaceutical composition, comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.
- 15. The pharmaceutical composition according to claim 14, comprising a compound according to claim 12 or 13, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.
- 16. A method for treating osteoarthritis or rheumatoid arthritis, comprising administering to a patient suffering from osteoarthritis or rheumatoid arthritis a nontoxic effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
- 17. The method according to claim 16, wherein the compound administered is a compound according to claim 12 or 13, or a pharmaceutically acceptable salt thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of priority from U.S. Provisional Patent Application No. 60/403,242, filed Aug. 13, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60403242 |
Aug 2002 |
US |